Fund Overview of Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw
-
₹950.3 CrAUM
-
₹24.16NAV
-
1.02%Expense Ratio
-
EquityFund Category
Minimum amount you can invest: ₹500
Maximum amount you can invest: ₹1,00,000
We have used a return rate of 15% for our calculations.
Returns of Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw
| Tenure | Absolute(%) | Annualised(%) | Category Average(%) |
|---|---|---|---|
| 3 Months | 9.49% | NA | 6.12% |
| 6 Months | 10.30% | NA | 12.92% |
| 1 Year | 13.02% | 13.02% | 6.04% |
| 2 Years | 24.29% | 11.49% | 24.93% |
| 3 Years | 89.37% | 23.72% | 25.71% |
| 5 Years | 95.40% | 14.34% | 19.91% |
Dividends are declared by the fund house based on the income generated from the underlying assets. While many mutual funds distribute dividends annually, the payout frequency ultimately depends on the fund house’s decision
Compare Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw with other mutual funds in the same category
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw
SBI Healthcare Opportunities Fund Direct Plan-growth
SBI Healthcare Opportunities Fund Direct Plan-idcw
Asset Allocation
equities
96.83%other assets or cash equivalents
3.17%Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw is one Equity mutual fund offered by Aditya Birla Sun Life Mutual Fund. Launched on 10 Jul 2019, the fund aims Long term capital growth. investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. It manages assets worth ₹950.3 crore as on Sun May 31, 2026. The expense ratio stands at 1.02%. Fund Manager Manager Education Fund Manager Manager EducationAbout Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw
The portfolio allocation consists of 96.83% in equities, 3.17% in other assets or cash equivalents.Managed by Dhaval Shah, it has delivered a return of 13.02% in the last year, a total return since inception of 20.81%.
The latest dividend was declared on 20 Feb 2026 at 14.10% of face value.
For those looking to make informed investment decisions it is useful to explore best sip in india that align with financial planning needs.
Key Metrics of Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw
-
Standard Deviation16.17%
-
Sharpe Ratio1.13%
-
Alpha0.75%
-
Beta0.92%
Fund Details
|
|
Top Performing Mutual Funds
| Fund Names | AUM (Cr) | 1M | 3M | 1Yr | 3Yr | 5Yr |
|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| Mirae Asset Healthcare Fund Direct-growth |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| Mirae Asset Healthcare Fund Direct-idcw |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| DSP Healthcare Fund Direct-growth |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| DSP Healthcare Fund Direct-idcw |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
| SBI Healthcare Opportunities Fund-idcw |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
More funds from Aditya Birla Sun Life Mutual Fund
| Fund Names | AUM (Cr) | 1M | 3M | 6M | 1Yr | 3Yr |
|---|---|---|---|---|---|---|
|
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-growth
|
₹950 | -0.24% | 9.49% | 10.30% | 13.02% | 23.72% |
|
Aditya Birla Sun Life Pharma & Healthcare Fund Regular-growth
|
₹950 | -0.36% | 9.14% | 9.57% | 11.54% | 22.08% |
|
Aditya Birla Sun Life Pharma & Healthcare Fund Regular-idcw
|
₹950 | -0.36% | 9.14% | 9.57% | 11.54% | 22.08% |
|
Aditya Birla Sun Life Nifty Healthcare Etf-growth
|
₹76 | -2.15% | 6.71% | 5.94% | 9.48% | 21.91% |
Mutual Fund Calculator
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
Top Mutual Funds
| Fund Names | AUM (Cr) | NAV | 3Yr | 5Yr | 10Yr |
|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth |
₹8,636 | ₹535.25 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-growth |
₹8,636 | ₹601.05 | 21.51% | 13.66% | 16.24% |
| Nippon India Pharma Fund-idcw |
₹8,636 | ₹115.58 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-idcw |
₹8,636 | ₹164.49 | 21.51% | 13.66% | 16.24% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth |
₹6,454 | ₹41.36 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,454 | ₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw |
₹6,454 | ₹24.13 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | ₹27.11 | 26.34% | 16.48% | - |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | ₹468.57 | 23.45% | 15.57% | 13.35% |
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹4,566 | ₹541.52 | 24.74% | 16.80% | 14.59% |
Detailed Portfolio
| Stocks | Sector | % of Holding | Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 12.42% | ₹118.04 Cr |
| Apollo Hospitals Enterprise Ltd | Healthcare | 7.31% | ₹69.45 Cr |
| Torrent Pharmaceuticals Ltd | Healthcare | 4.75% | ₹45.19 Cr |
| Jb Chemicals & Pharmaceuticals Ltd | Healthcare | 4.73% | ₹44.97 Cr |
| Aurobindo Pharma Ltd | Healthcare | 4.37% | ₹41.54 Cr |
| Ajanta Pharma Ltd | Healthcare | 3.99% | ₹37.87 Cr |
| Mankind Pharma Ltd. | Healthcare | 3.89% | ₹36.96 Cr |
| Lupin Ltd | Healthcare | 3.73% | ₹35.42 Cr |
| Abbott India Ltd | Healthcare | 3.65% | ₹34.73 Cr |
| Fortis Healthcare Ltd | Healthcare | 3.31% | ₹31.48 Cr |
| Reverse Repo | Unspecified | 3.23% | ₹30.66 Cr |
| Emcure Pharmaceuticals Ltd. | Healthcare | 3.17% | ₹30.15 Cr |
| Cipla Ltd | Healthcare | 2.98% | ₹28.31 Cr |
| Shilpa Medicare Ltd | Healthcare | 2.92% | ₹27.79 Cr |
| Ipca Laboratories Ltd | Healthcare | 2.43% | ₹23.10 Cr |
| Sai Life Sciences Ltd. | Healthcare | 2.26% | ₹21.46 Cr |
| Procter & Gamble Health Ltd | Healthcare | 2.24% | ₹21.31 Cr |
| Corona Remedies Ltd. | 2.06% | ₹19.61 Cr | |
| Alkem Laboratories Ltd | Healthcare | 2.03% | ₹19.26 Cr |
| Thyrocare Technologies Ltd | Healthcare | 1.89% | ₹17.95 Cr |
Top Equity Funds
| Fund Names | NAV | 3Yr | 5Yr | 52 weeks high |
|---|---|---|---|---|
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹541.52 | 24.74% | 16.80% | - |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹376.23 | 24.74% | 16.80% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹27.11 | 26.34% | 16.48% | - |
| Mirae Asset Healthcare Fund Direct-growth |
₹47.24 | 24.88% | 15.73% | - |
| Mirae Asset Healthcare Fund Direct-idcw |
₹28.45 | 24.88% | 15.73% | - |
| DSP Healthcare Fund Direct-growth |
₹46.19 | 22.68% | 15.62% | - |
| DSP Healthcare Fund Direct-idcw |
₹26.71 | 22.68% | 15.62% | - |
| SBI Healthcare Opportunities Fund-growth |
₹468.57 | 23.45% | 15.57% | - |
| SBI Healthcare Opportunities Fund-idcw |
₹295.17 | 23.45% | 15.57% | - |
Frequently Asked Questions
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw
What is the current AUM of Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw?
As of Sun May 31, 2026, Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw manages assets worth ₹950.3 crore
How has Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw performed recently?
- 3 Months: 9.49%
- 6 Months: 10.30%
What is the long-term performance of Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw?
- 3 Years CAGR: 23.72%
- 5 Years CAGR: 14.34%
- Since Inception: 20.81%
What is the portfolio composition of Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw?
Equity: 96.83%, Others: 3.17%.
Who manages Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw?
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw is managed by Dhaval Shah from Aditya Birla Sun Life Mutual Fund.
When was the last dividend declared by Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw?
Latest dividend was declared on 20 Feb 2026 at 14.10% of face value.
What is the market-cap allocation of Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw?
Large Cap: 32.38%, Mid Cap: 27.39%, Small Cap: 40.22%.
Which are the top companies Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw has invested in?
- Sun Pharmaceutical Industries Ltd – 12.42% of the fund's portfolio
- Apollo Hospitals Enterprise Ltd – 7.31% of the fund's portfolio
- Torrent Pharmaceuticals Ltd – 4.75% of the fund's portfolio
- JB Chemicals & Pharmaceuticals Ltd – 4.73% of the fund's portfolio
- Aurobindo Pharma Ltd – 4.37% of the fund's portfolio
Which are the major sectors Aditya Birla Sun Life Pharma & Healthcare Fund Direct-idcw focuses on?
- Healthcare – 72.08% of the fund's portfolio
- Unspecified – 3.23% of the fund's portfolio
- Other – 2.06% of the fund's portfolio
Policybazaar does not endorse rates/returns or recommend any particular insurer, fund house, AMC (Asset Management Company), insurance and mutual fund product.
Please consult your financial advisor for an informed decision.
Past performance may not be indicative of future results.
The information presented on this page is not owned or generated by Policybazaar. The data has been collected from publicly available sources and online research. We do not claim any ownership or guarantee the accuracy, completeness, or timeliness of this information. It is shared solely for the informational purpose of the viewer and should not be considered as financial advice.
Policybazaar is not acting as a financial advisor, broker, or agent for any mutual fund mentioned here.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
Policybazaar shall not be held responsible or liable for any losses, damages, or decisions made based on the information provided on this page.
For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product. For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product.
For more details on risk factors, terms, and conditions, please read the sales brochure and benefit illustration carefully before concluding a sale.
Policybazaar is a registered Insurance Broker | Registration No. 742, Registration Code No. IRDA/ DB 797/ 19, Valid till 09/06/2024, License category- Direct Broker (Life & General) |CIN: U74999HR2014PTC053454 | Registered Office - Plot No.119, Sector - 44, Gurgaon, Haryana – 122001 |Visitors are hereby informed that their information submitted on the website may be shared with insurers. Product information is authentic and solely based on the information received from the insurers.©️ Copyright 2008-2025 policybazaar.com. All Rights Reserved
^Returns as on 10th Jan’25. Tata AIA Life Top 200 ULIP Fund has delivered 18% returns over the last 10 years. Past performance is not necessarily indicative of future results. This disclaimer is specifically regarding a ULIP fund and is not related to mutual funds. Source: Morningstar.





